20:51 , Jun 16, 2017 |  BC Week In Review  |  Company News

GeneriCo wins IPR for Apriso

In a May...
08:00 , Nov 10, 2014 |  BioCentury  |  Finance

Convert resurgence

Biotechs have raised $5.6 billion through convertible debt financings so far this year, the highest amount since 2006. Two bankers attributed the resurgence to a growing mid-cap space that is taking advantage of low interest...
03:27 , Nov 7, 2014 |  BC Extra  |  Top Story

Salix hit on accounting turmoil

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) plunged $53.05 (38%) to $85.50 in after-hours trading on Thursday on news its CFO had resigned and the company had retained outside counsel to investigate how it was accounting for inventory...
07:00 , Aug 11, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) was up $0.44 to $22.47 last week after submitting a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. AIGIV is being developed...
07:00 , May 12, 2014 |  BioCentury  |  Finance

Zeroing in on immunity

Investors in Anokion S.A. 's CHF33 million ($37.6 million) series A round think the company's antigen-specific approach to inducing immune tolerance will lead to less immunogenic formulations of existing cancer and hematology drugs, as well...
08:00 , Mar 3, 2014 |  BioCentury  |  Finance

Spreading six

Abingworth's sixth flagship fund likely will put more money towards the opposite ends of the firm's investment universe - start-ups and public companies. The new fund closed last week at £225 million ($375 million). Seven...
08:00 , Nov 11, 2013 |  BioCentury  |  Finance

OrbiMed's high five

At a time when many life science VCs are raising smaller funds, OrbiMed Advisors closed what might be the largest pure venture fund in over a decade, raising more than $735 million from LPs who...
07:00 , Aug 12, 2013 |  BioCentury  |  Finance

Signed and sealed

ProFibrix B.V. reached the one-yard line with its Fibrocaps based on €40 million in equity funding, but rather than amass commercial scale to compete in the surgical products market, the company accepted a takeout bid...
07:00 , May 13, 2013 |  BioCentury  |  Finance

Watch me launch

Isis Pharmaceuticals Inc. (NASDAQ:ISIS) didn't wait for investors to learn launch details of hypercholesterolemia drug Kynamro mipomersen. Instead, the biotech took advantage of recent share price gains to raise $171 million in the largest follow-on...
08:00 , Mar 4, 2013 |  BioCentury  |  Finance

Amgen's Omontys bounce

Amgen Inc. (NASDAQ:AMGN) added $2 billion in market cap last Monday, which was nearly four times the value shaved off competitor Affymax Inc. (NASDAQ:AFFY) when the latter recalled its once-monthly anemia drug Omontys peginesatide. Amgen...